BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1821 related articles for article (PubMed ID: 30225928)

  • 21. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effect of angiotensin converting enzyme inhibitor versus angiotensin ii type i receptor blocker in acute myocardial infarction with non-obstructive coronary arteries; from the Korea Acute Myocardial Infarction Registry - National Institute of Health.
    Ahn JH; Hyun JY; Jeong MH; Kim JH; Hong YJ; Sim DS; Kim MC; Park HS; Kim DI; Hur SH; Oh SK; Ahn Y
    Cardiol J; 2021; 28(5):738-745. PubMed ID: 33001422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis.
    Darabian S; Luo Y; Homat A; Khosraviani K; Wong N; Zeb I; Nasir K; Budoff MJ
    Coron Artery Dis; 2015 Dec; 26(8):678-85. PubMed ID: 26398149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension.
    Her AY; Choi BG; Rha SW; Kim YH; Choi CU; Jeong MH
    PLoS One; 2020; 15(11):e0242314. PubMed ID: 33253206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationships between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients with Diabetes.
    Raebel MA; Dyer W; Nichols GA; Goodrich GK; Schmittdiel JA
    Pharmacotherapy; 2017 Oct; 37(10):1204-1214. PubMed ID: 28752555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
    Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
    Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
    Mayyas F; Bataineh W; Jarab A
    Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
    Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
    JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention.
    Ann SH; Strauss MH; Park GM; Han S; Yang Y; Kim YG; Won KB; Kim SJ; Lee SG; Cho YR; Kim DW; Park MW; Her SH; Lee SW
    Int J Cardiol; 2020 May; 306():35-41. PubMed ID: 31727411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
    An J; Niu F; Sim JJ
    Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association between renin angiotensin aldosterone system blockers and future osteoporotic fractures in a hypertensive population - A population-based cohort study in Taiwan.
    Kao YT; Huang CY; Fang YA; Liu JC
    Int J Cardiol; 2020 Apr; 305():147-153. PubMed ID: 31955975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying adherent patients to newly initiated statins using previous adherence to chronic medications.
    Majd Z; Mohan A; Paranjpe R; Abughosh SM
    J Manag Care Spec Pharm; 2021 Feb; 27(2):186-197. PubMed ID: 33506725
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
    J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis.
    Ma J; Khalidi N; Wierzbicki O; Alqutami A; Ioannidis G; Pagnoux C
    Int J Rheum Dis; 2020 Aug; 23(9):1233-1239. PubMed ID: 32776676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
    Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
    Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of Viral Infection in Patients Using Either Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Nationwide Population-based Propensity Score Matching Study.
    Lin SY; Ju SW; Lin CL; Lin CC; Hsu WH; Chou CH; Chi CY; Hsu CY; Kao CH
    Clin Infect Dis; 2020 Dec; 71(10):2695-2701. PubMed ID: 32504531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
    Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
    BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage after Infrapopliteal Interventions for Critical Limb Ischemia.
    Khan SZ; Montross B; Rivero M; Cherr GS; Harris LM; Dryjski ML; Dosluoglu HH
    Ann Vasc Surg; 2020 Feb; 63():275-286. PubMed ID: 31626938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
    Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
    Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 92.